Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million

Stock Information for Galera Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Galera Therapeutics Inc.

Galera Therapeutics completes acquisition of Nova Pharmaceuticals
Galera Announces Board Approval of Complete Liquidation and Dissolution
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
Galera Adopts Limited Duration Stockholder Rights Agreement
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.